 Connection
Jason Glanz to Opioid-Related Disorders
This is a "connection" page, showing publications Jason Glanz has written about Opioid-Related Disorders.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.043 |
|
|
|
-
Nguyen AP, Binswanger IA, Narwaney KJ, Goodrich G, Christine PJ, Campbell CI, Xu S, Loree AM, Glanz JM. Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder. JAMA Psychiatry. 2026 May 01; 83(5):491-498.
Score: 0.539
-
Xu S, Narwaney KJ, Nguyen AP, Binswanger IA, McClure DL, Glanz JM. An individual segmented trajectory approach for identifying opioid use patterns using longitudinal dispensing data. Pharmacoepidemiol Drug Saf. 2024 01; 33(1):e5708.
Score: 0.451
-
Glanz JM, Xu S, Narwaney KJ, McClure DL, Rinehart DJ, Ford MA, Nguyen AP, Binswanger IA. Association Between Opioid Dose Reduction Rates and Overdose Among Patients Prescribed Long-Term Opioid Therapy. Subst Abus. 2023 07; 44(3):209-219.
Score: 0.449
-
Binswanger IA, Shetterly SM, Xu S, Narwaney KJ, McClure DL, Rinehart DJ, Nguyen AP, Glanz JM. Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment. JAMA Netw Open. 2022 10 03; 5(10):e2234671.
Score: 0.420
-
Glanz JM, Binswanger IA, Clarke CL, Nguyen AP, Ford MA, Ray GT, Xu S, Hechter RC, Yarborough BJH, Roblin DW, Ahmedani B, Boscarino JA, Andrade SE, Rosa CL, Campbell CI. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment. Addiction. 2023 01; 118(1):97-107.
Score: 0.415
-
Binswanger IA, Rinehart D, Mueller SR, Narwaney KJ, Stowell M, Wagner N, Xu S, Hanratty R, Blum J, McVaney K, Glanz JM. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial. J Gen Intern Med. 2022 08; 37(11):2624-2633.
Score: 0.402
-
Wagner NM, Binswanger IA, Shetterly SM, Rinehart DJ, Wain KF, Hopfer C, Glanz JM. Development and validation of a prediction model for opioid use disorder among youth. Drug Alcohol Depend. 2021 10 01; 227:108980.
Score: 0.390
-
Shoup JA, Mueller SR, Binswanger IA, Williams AV, Strang J, Glanz JM. Modifying and Evaluating the Opioid Overdose Knowledge Scale for Prescription Opioids: A Pilot Study of the Rx-OOKS. Pain Med. 2020 10 01; 21(10):2244-2252.
Score: 0.366
-
Binswanger IA, Glanz JM. Pharmaceutical Opioids in the Home and Youth: Implications for Adult Medical Practice. Subst Abus. 2015; 36(2):141-3.
Score: 0.248
-
Guan X, Jurecka C, Padmanabhan P, Yamkovoy K, Christine PJ, Binswanger IA, Glanz JM, Kline DM, Barocas JA. Impact of increased criminal penalties for fentanyl possession on initiation and retention on medications for opioid use disorder in Colorado. Int J Drug Policy. 2025 12; 146:105037.
Score: 0.130
-
Nguyen AP, Glanz JM, Shoup JA, Campbell CI, Clarke CL, Ford MA, Binswanger IA. Mortality Among Patients Prescribed Buprenorphine for Opioid Use Disorder After Disenrollment from an Insurance Plan and Healthcare System. J Gen Intern Med. 2022 08; 37(11):2882-2884.
Score: 0.100
-
Binswanger IA, Glanz JM. Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. Drug Saf. 2018 10; 41(10):979-980.
Score: 0.080
-
Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend. 2013 Aug 01; 131(3):263-70.
Score: 0.054
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|